Market entry is a yes / no / not-like-this decision. The tree is four questions: is the pond worth it, can we catch fish there, how do we enter, and what kills us. Touring “the market” for eight minutes with no verdict is a fail. Naming a famous 3-box is optional; sequencing these four is not.
The tree
| Branch | What you prove | A number that belongs here |
|---|---|---|
| Attractiveness | Size, growth, profit pool, barriers | $ TAM, growth, typical margin |
| Right to win | Why a UK clinic picks us | Cost-to-serve, spec gap, references |
| Mode | Export, partner, acquire, greenfield | Time to first $ , capital, control |
| Risks | Regulatory, competitive response, execution | Fine, delay, share we never get |
Do not dump political–economic–social–technological as a fifth tour. If regulation matters, it sits under attractiveness (can we legally sell) or risk (license delay). If it does not move the decision, skip it.
Worked example: US dental SaaS into the UK
Prompt. BiteGrid sells practice-management software to US dental groups. ACV $14k, 2,100 logos, NRR 108%. The board wants the UK in year 1 because “NHS dentistry is in crisis and private is booming.”
Attractiveness (do not skip the unit). UK private dentistry: ~12,000 private-leaning practices (not every NHS high-street chair). Willing-to-pay for software is lower: UK incumbents charge £3–6k ACV. Use £4,500 ≈ $5,700. TAM ≈ 12,000 × $5,700 ≈ $68m. US TAM they already address is ~$2.1k × $14k ≈ $29m wait — 2,100 customers, not the whole US. US market they could still penetrate is larger; point is UK ACV is ~40% of US ACV. Growth 6% real. Attractive as a small pond, not as a second United States. Profit pool: UK dental software is crowded (two incumbents >30% share each). Attractiveness is moderate, not a land grab.
Right to win. BiteGrid’s product assumes US insurance coding, patient financing, and Delta Dental workflows. UK private practices care about NHS/private mix, recall compliance, and HMRC-friendly reporting. Building that is not a config flag. Two US features they love (clear aligner tracking, membership plans) do map. Right to win is narrow: private groups of 4+ sites that already copy US DSO playbooks. That is maybe 800 sites, not 12,000. Realistic year-3 share of that niche 10% = 80 logos × $5,700 = $0.46m ARR. That does not pay for a London office.
Mode. Greenfield sales hire in London: $1.1m/year burn before ARR. Partnership with a UK imaging vendor: slower, 20% rev share, but $0.2m cost. Acquire a 40-logo UK vendor at 8× $1.2m revenue = $9.6m — now you have product and a book. Mode ranking: partner or small acquire, not a UK HQ.
Risks. MHRA/DTAC-ish NHS Digital requirements if they touch NHS work — a two-year slog. The two incumbents can discount 20% to strand a US entrant. FX: ACV in GBP, costs in USD if product stays in Austin — manageable.
Recommendation. Do not “enter the UK” as a market. Pilot a partner-led motion to US-style DSO roll-ups only (the 800). Kill if 12 logos are not signed in 12 months. Do not staff London. The board’s NHS-crisis story is a newspaper, not a TAM.
When market entry is the wrong tree
The client already operates there and profit fell. That is profitability, not entry.
The question is which product to launch in the home market. That is new product or Ansoff sequencing.
The question is buy this company. If the only mode is a live deal, use M&A. Entry is the parent; the live bid is the child.
The mistake unique to entry cases
Sizing the country instead of the buyer. “UK healthcare is 10% of GDP” is a TV statistic. BiteGrid sells to practice owners at a GBP ACV. Wrong object, wrong TAM, wrong office.
The second unique fail is skipping mode. “Yes, enter” with no partner/acquire/greenfield is a slogan. Mode changes IRR by 10× in this example.
How to open
“I will test whether the UK profit pool is worth it at UK prices, whether our US product actually wins a named buyer, how we would enter without a London burn, and what regulation or incumbent discounting does to that plan.”
Then put $68m TAM, $0.46m realistic ARR, and $1.1m greenfield burn on one line. The comparison is the recommendation.
A useful pressure test: would you spend the $1.1m in the home market instead? BiteGrid still has US logos to penetrate at $14k ACV. $1.1m of extra US sales capacity that closed even 40 logos would add ~$0.56m ARR at US prices, with a product that already fits. That alternative does not make the UK illegal. It makes a London office the wrong use of the same cash until the 800-site niche is proven through a partner.
Test attractiveness before you staff a country
Structure a live prompt where the glamorous geography is the decoy. Grade the mode and the realistic buyer.